

Evanthia Diamanti-Kandarakis

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/11632374/evanthia-diamanti-kandarakis-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

13,795
citations

48
h-index

109
g-index

109
ext. papers

15,572
ext. citations

5.4
avg, IF

6.39
L-index

#	Paper	IF	Citations
107	Endocrine-disrupting chemicals: an Endocrine Society scientific statement. <i>Endocrine Reviews</i> , 2009 , 30, 293-342	27.2	2820
106	Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4237-45	5.6	1491
105	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. <i>Fertility and Sterility</i> , 2009 , 91, 456-88	4.8	1268
104	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. <i>Endocrine Reviews</i> , 2012 , 33, 981-1030	27.2	928
103	A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4006-11	5.6	792
102	Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 2038-49	5.6	669
101	The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , 2014 , 171, P1-29	6.5	346
100	Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E480-4	5.6	238
99	Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. <i>Nature Communications</i> , 2015 , 6, 7502	17.4	214
98	Molecular mechanisms of insulin resistance in polycystic ovary syndrome. <i>Trends in Molecular Medicine</i> , 2006 , 12, 324-32	11.5	199
97	Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. <i>Human Reproduction</i> , 2006 , 21, 1426-31	5.7	193
96	Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , 2008 , 10, e3	6.7	174
95	Pathophysiology and types of dyslipidemia in PCOS. <i>Trends in Endocrinology and Metabolism</i> , 2007 , 18, 280-5	8.8	174
94	Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 4666-73	5.6	173
93	Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2010 , 162, 193-212	6.5	155
92	Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2008 , 69, 634-41	3.4	137
91	A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1927-32	5.6	129

90	Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2005 , 62, 37-43	3.4	129
89	Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1273-6	5.6	127
88	Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. <i>Histochemistry and Cell Biology</i> , 2007 , 127, 581-9	2.4	125
87	Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. <i>Clinical Endocrinology</i> , 2007 , 67, 735-42	3.4	119
86	Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. <i>Human Reproduction Update</i> , 2005 , 11, 631-43	15.8	117
85	The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2699-705	5.6	116
84	PCOS Forum: research in polycystic ovary syndrome today and tomorrow. <i>Clinical Endocrinology</i> , 2011 , 74, 424-33	3.4	102
83	Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. <i>Clinical Chemistry</i> , 2005 , 51, 1691-7	5.5	101
82	The role of genes and environment in the etiology of PCOS. <i>Endocrine</i> , 2006 , 30, 19-26		98
81	Insulin resistance in PCOS. <i>Endocrine</i> , 2006 , 30, 13-7		92
80	Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006 , 85, 420-7	4.8	84
79	Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2000 , 73, 735-41	4.8	83
78	Polycystic ovary syndrome and environmental toxins. <i>Fertility and Sterility</i> , 2016 , 106, 948-58	4.8	81
77	Indices of low-grade inflammation in polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1092, 175-86	6.5	79
76	Polycystic ovary syndrome: the influence of environmental and genetic factors. <i>Hormones</i> , 2006 , 5, 17-34	3.1	76
75	The effects of old, new and emerging medicines on metabolic aberrations in PCOS. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2012 , 3, 27-47	4.5	75
74	Accumulation of dietary glycotoxins in the reproductive system of normal female rats. <i>Journal of Molecular Medicine</i> , 2007 , 85, 1413-20	5.5	73
73	Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006 , 85, 1778-83	4.8	67

72	Metformin in polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1205, 192-8	6.5	64
71	The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. <i>European Journal of Endocrinology</i> , 2004 , 150, 793-8	6.5	64
70	Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008 , 109, 242-6	5.1	62
69	European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group® Questionnaire. <i>European Journal of Endocrinology</i> , 2014 , 171, 489-98	6.5	61
68	Phenotypes and enviromental factors: their influence in PCOS. <i>Current Pharmaceutical Design</i> , 2012 , 18, 270-82	3.3	61
67	Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , 2007 , 56, 129-34	12.7	60
66	Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015 , 16, 365-71	10.5	59
65	Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). <i>Hormones</i> , 2014 , 13, 65-73	3.1	59
64	Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. <i>Human Reproduction</i> , 2008 , 23, 1439-46	5.7	59
63	New perspectives in polycystic ovary syndrome. <i>Trends in Endocrinology and Metabolism</i> , 1996 , 7, 267-71	18.8	51
62	Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial. <i>Stress</i> , 2015 , 18, 57-66	3	49
61	Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2009 , 160, 847-53	6.5	48
60	PCOS in adolescents. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2010 , 24, 173-83	4.6	48
59	Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2-NF- κ B and JNK-AP-1 signaling pathways. <i>Cellular and Molecular Life Sciences</i> , 2016 , 73, 1685-98	10.3	47
58	Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. <i>Endocrine</i> , 2014 , 47, 631-8	4	46
57	Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. <i>Women's Health</i> , 2008 , 4, 583-94	3	45
56	Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. <i>Sports Medicine</i> , 2005 , 35, 831-40	10.6	45
55	Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 2460-9	5.6	42

54	Metabolic syndrome and polycystic ovary syndrome... and vice versa. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2009 , 53, 227-37		40
53	Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. <i>Human Reproduction</i> , 2005 , 20, 2127-32	5.7	39
52	Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 255-274	5.5	38
51	In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. <i>Hormones</i> , 2009 , 8, 199-206	3.1	37
50	Advanced glycation end-products and insulin signaling in granulosa cells. <i>Experimental Biology and Medicine</i> , 2016 , 241, 1438-45	3.7	35
49	Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome?. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, 1564-73	12.7	34
48	Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome. <i>European Journal of Endocrinology</i> , 2014 , 171, 301-9	6.5	33
47	Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. <i>Clinical Endocrinology</i> , 2011 , 75, 698-703	3.4	33
46	Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress. <i>Anemia</i> , 2013 , 2013, 617204	1.6	31
45	Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 494-500	12.7	31
44	Insulin resistance and polycystic ovary syndrome through life. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5569-76	3.3	30
43	Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?. <i>European Journal of Endocrinology</i> , 2008 , 158, 525-31	6.5	30
42	The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome		30
41	Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2014 , 81, 426-31	3.4	28
40	Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. <i>Fertility and Sterility</i> , 2013 , 99, 943-50	4.8	28
39	Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. <i>Hormones</i> , 2006 , 5, 126-36	3.1	28
38	Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2007 , 66, 103-9	3.4	26
37	Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander?. <i>Hormones</i> , 2011 , 10, 292-7	3.1	25

36	Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. <i>Journal of Bone and Mineral Metabolism</i> , 2011 , 29, 201-6	2.9	25
35	Implications and Future Perspectives of AGEs in PCOS Pathophysiology. <i>Trends in Endocrinology and Metabolism</i> , 2019 , 30, 150-162	8.8	23
34	MECHANISMS IN ENDOCRINOLOGY: Nutrition as a mediator of oxidative stress in metabolic and reproductive disorders in women. <i>European Journal of Endocrinology</i> , 2017 , 176, R79-R99	6.5	23
33	Targets to treat metabolic syndrome in polycystic ovary syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 1561-74	6.4	23
32	Androgens associated with advanced glycation end-products in postmenopausal women. <i>Menopause</i> , 2010 , 17, 1182-7	2.5	22
31	Hormone replacement therapy and risk of malignancy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2004 , 16, 73-8	2.4	22
30	Polycystic ovary syndrome--phenotypes and diagnosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014 , 244, 18-22; discussion 21	2	20
29	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. <i>Endocrine</i> , 2012 , 42, 526-34	4	19
28	MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects. <i>European Journal of Endocrinology</i> , 2016 , 175, R157-69	6.5	18
27	Stress in women: metabolic syndrome and polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1083, 54-62	6.5	18
26	Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2013 , 168, R33-43	6.5	16
25	Is there an association between thyroid function abnormalities and breast cancer?. <i>Archives of Endocrinology and Metabolism</i> , 2017 , 61, 54-61	2.2	16
24	Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. <i>Hormones</i> , 2003 , 2, 61-6	3.1	16
23	Does polycystic ovary syndrome start in childhood?. <i>Pediatric Endocrinology Reviews</i> , 2008 , 5, 904-11	1.1	16
22	Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review. <i>Frontiers in Endocrinology</i> , 2019 , 10, 388	5.7	15
21	Insulin Resistance in PCOS 2009 , 35-61		14
20	Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. <i>Kidney and Blood Pressure Research</i> , 2009 , 32, 24-31	3.1	13
19	The role of stress in PCOS. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 87-95	4.1	12

18	White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandrogenemia. <i>Hormones</i> , 2015 , 14, 91-100	3.1	11
17	The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. <i>Hormones</i> , 2014 , 13, 488-97	3.1	10
16	Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome. <i>Current Obesity Reports</i> , 2014 , 3, 377-86	8.4	8
15	The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond. <i>Current Pharmaceutical Design</i> , 2011 , 17, 908-21	3.3	8
14	Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma. <i>Cancer</i> , 2003 , 97, 12-20	6.4	7
13	Endocrine disruptors and polycystic ovary syndrome: a focus on Bisphenol A and its potential pathophysiological aspects. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2014 , 17, 137-44	1.3	6
12	Impact of diet-induced obesity in male mouse reproductive system: The role of advanced glycation end product-receptor for advanced glycation end product axis. <i>Experimental Biology and Medicine</i> , 2014 , 239, 937-947	3.7	5
11	How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?. <i>Journal of Endocrinological Investigation</i> , 1998 , 21, 623-9	5.2	4
10	Tailoring treatment for PCOS phenotypes. <i>Expert Review of Endocrinology and Metabolism</i> , 2021 , 16, 9-18	4.1	4
9	Conservative management of gynecologic diseases: insulin sensitizing agents in polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , 2003 , 997, 322-9	6.5	3
8	Hormones in sports: growth hormone abuse. <i>Hormones</i> , 2004 , 3, 37-45	3.1	3
7	Update on polycystic ovary syndrome. <i>Women's Health</i> , 2006 , 2, 561-9	3	2
6	Novel insights into the pathophysiology of PCOS: the role of environmental toxins 2013 , 38-48		1
5	Insulin Sensitizers Targeting Metabolic and Reproductive Consequences in Polycystic Ovary Syndrome 2008 , 197-215		1
4	Pharmaceutical Intervention in Metabolic and Cardiovascular risk Factors in Polycystic Ovary Syndrome 2007 , 431-449		1
3	Endocrine-disrupting chemicals and PCOS: A novel contributor in the etiology of the syndrome 2022 , 227-244		0
2	Additive effects of dietary glycotoxins and androgen excess on the kidney of a female rat modelPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 8 August 2015View all notes. <i>Alexandria Journal of Medicine</i> , 2016 , 52, 159-168	0.7	
1	Novel insights into the pathophysiology and treatment of polycystic ovary syndrome 2013 , 2-4		

